| scholarly article | Q13442814 |
| P2093 | author name string | Julie Hambleton | |
| Steven R Kayser | |||
| Mai-Trang N Dang | |||
| P2860 | cites work | Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site | Q28218180 |
| Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing | Q32049910 | ||
| Long-term treatment with warfarin in Chinese population | Q34122505 | ||
| Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. | Q36054252 | ||
| Factors affecting the maintenance dose of warfarin | Q37110242 | ||
| Aging and the anticoagulant response to warfarin therapy | Q43672961 | ||
| Interindividual variability in sensitivity to warfarin--Nature or nurture? | Q43705893 | ||
| Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients | Q43757356 | ||
| Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy | Q43857914 | ||
| Patient-specific factors predictive of warfarin dosage requirements | Q44146616 | ||
| CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians | Q44365394 | ||
| Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. | Q46256641 | ||
| Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes | Q47961549 | ||
| Factors determining the maintenance dose of warfarin in Chinese patients. | Q51020114 | ||
| Differences in plasma binding of drugs between Caucasians and Chinese subjects. | Q51731148 | ||
| Effect of ageing upon warfarin dose requirements: a longitudinal study. | Q52291861 | ||
| Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination. | Q54640269 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | (RS)-warfarin | Q407431 |
| P304 | page(s) | 1008-1012 | |
| P577 | publication date | 2005-04-26 | |
| P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
| P1476 | title | The influence of ethnicity on warfarin dosage requirement | |
| P478 | volume | 39 |
| Q45996594 | A visual medication schedule to improve anticoagulation control: a randomized, controlled trial. |
| Q46466680 | Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort |
| Q50993101 | An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population. |
| Q57798345 | Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent |
| Q37274009 | Atrial Fibrillation and Race - A Contemporary Review |
| Q53099910 | Bleeding events and associated factors in a cohort of adult patients taking warfarin in Sarawak, Malaysia. |
| Q57293266 | Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White? |
| Q36487290 | Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics? |
| Q34096562 | Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. |
| Q38958252 | Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review |
| Q42791847 | Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations |
| Q58558658 | Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients |
| Q47189066 | Dedicated warfarin care programme results in superior warfarin control in Queensland, Australia. |
| Q54935902 | Disease burden and the role of pharmacogenomics in African populations. |
| Q38851927 | Drug Treatment of Venous Thromboembolism in the Elderly. |
| Q28276514 | Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin |
| Q36661285 | Effect of patient-specific factors on weekly warfarin dose |
| Q44321220 | Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation |
| Q36314728 | Effects of VKORC1 Genetic Polymorphisms on Warfarin Maintenance Dose Requirement in a Chinese Han Population. |
| Q52603891 | Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation. |
| Q46265412 | Establishing an oral anticoagulant monitoring service in a multiethnic developing country |
| Q37276490 | Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics |
| Q37264555 | Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics |
| Q34628256 | Evaluation of a required senior research project in a doctor of pharmacy curriculum |
| Q42722363 | Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism |
| Q53964537 | Higher Risk of Bleeding in Asians Presenting With ST Elevation Myocardial Infarction (STEMI). |
| Q33613526 | Increased genetic diversity of ADME genes in African Americans compared with their putative ancestral source populations and implications for pharmacogenomics |
| Q37376879 | Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans |
| Q34655124 | Influence of ethnic origin and sex on the pharmacokinetics of clazosentan |
| Q38180988 | New oral anticoagulants in practice: pharmacological and practical considerations |
| Q37867275 | Patient factors that influence warfarin dose response |
| Q24814457 | Pharmacogenetics in the management of coumarin anticoagulant therapy: the way forward or an expensive diversion? |
| Q36543128 | Pharmacogenetics of chronic cardiovascular drugs: applications and implications |
| Q46862790 | Pharmacokinetics and tolerability of almorexant in Japanese and Caucasian healthy male subjects |
| Q46899663 | Population variation in VKORC1 haplotype structure |
| Q38725359 | Prediction of biogeographical ancestry from genotype: a comparison of classifiers. |
| Q36835168 | Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement |
| Q35644607 | Relationship between the Occurrence of Thromboembolism and INR Measurement Interval in Low Intensity Anticoagulation after Aortic Mechanical Valve Replacement |
| Q51357889 | Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. |
| Q38264260 | Review of race/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials |
| Q46316268 | Shifting paradigms in the pharmacogenetics of warfarin |
| Q40285992 | Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors |
| Q91639524 | The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation? |
| Q92087148 | The Effect of Demographic Factors and VKORC1 1639 G>A Genotypes on Estimated Warfarin Maintenance Dose in Iranian Patients Under Warfarin Therapy |
| Q46573199 | The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations. |
| Q34530230 | The future prospects of pharmacogenetics in oral anticoagulation therapy |
| Q43609145 | The need for multicentre cardiovascular clinical trials in Asia |
| Q90441791 | Towards precision medicine: interrogating the human genome to identify drug pathways associated with potentially functional, population-differentiated polymorphisms |
| Q37074097 | Use of genetic and nongenetic factors in warfarin dosing algorithms |
| Q35654365 | Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: is there a treatment disparity? |
| Q46238853 | VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients |
| Q36982736 | VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans |
| Q45749835 | Vitamin K epoxide reductase complex 1 (VKORC1) haplotypes in healthy Hungarian and Roma population samples. |
| Q33770184 | Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study |
| Q38696567 | Warfarin Pharmacogenomics in Diverse Populations. |
| Q61850138 | Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians |
| Q39862947 | Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. |
Search more.